India, April 25 -- Intellia Therapeutics (NTLA) will release topline results from its global Phase 3 HAELO clinical trial evaluating Lonvoguran ziclumeran (lonvo-z) for hereditary angioedema on April 27, 2026, Monday, marking a key milestone for what the company describes as the world's first Phase 3 readout for an in vivo CRISPR gene-editing candidate.
Hereditary angioedema (HAE) is a rare genetic disorder that causes sudden, severe swelling episodes affecting the skin, gastrointestinal tract, and airways. These attacks can be unpredictable and debilitating, making long-term prevention a major treatment goal for patients.
The HAELO study is designed to evaluate whether Lonvoguran ziclumeran - a one-time, in vivo CRISPR-based therapy - ca...